FDA approves new oral fumarate drug Vumerity for treatment of recurrent multiple sclerosis
-
Last Update: 2020-06-07
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
today, http://
the u.SFDA(http://officially approved its new oral fumaratedrug(http://) for the treatment of recurrent multiple sclerosis (MS) patients,announcedVumerity is a precursor to oral fumarateIt can be quickly converted into methylene sulprates in the bodyMomaracid monomethylesters can reduce damage from oxidative stress by activating a transcription factor called Nrf2This approval is based on Vumerity's performance in two Phase 3 clinicaltrial(http://In a trial called EVOLVE-MS-2, the proportion of patients who withdrew from the trial because of adverse events (AE) was 1.6% in the Vumerity treatment group, compared with 6.0% in the active control group of tecfidera, an approved metforma teracutane therapy , the proportion of patients who withdrew from the trial due to adverse events in the gastrointestinal (GI) was 0.8% in the treatment group and 4.8% in the active control group Another mid-term study, called THE EVOLVE-MS-1 trial, showed that the proportion of patients who withdrew from the trial because of all AE was 6.3 percent Of these, the proportion of patients who withdrew from the trial due to GI adverse events was less than 1%
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
